Phase 3 results for Sun Pharma’s investigational psoriasis medicine, tildrakizumab

Sun Pharma has announced late-breaking data from two pivotal Phase-3 clinical trials (reSURFACE 1 and 2) achieving the primary endpoint...

Read More